Innoveren Scientific Inc (IVRN)

[patentminer2013]

Medovex Corporation DenerveX System Reports on First Two Completed Cases in Germany

"DenerveX™ System has great potential in the treatment of Facet Joint Pain and could become the new standard of care."

ATLANTA, GA -- (Marketwired) -- 08/01/17 -- Medovex Corp. (NASDAQ: MDVX) ("Medovex" or the "Company"), the developer of the DenerveX™ System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to back pain, today reported initial results from the first cases conducted in Germany.


On July 26, 2017, Dr. Martin Deeg performed two cases in Stuttgart. Dr. Deeg is a member of the Company's European Medical Advisory Board.

Case summary from Dr. Deeg's cases:

Case One: Female, 40 years old, L4, two joints treated. Patient had injection local only at the facet joint. At the end of the procedure the patient moved herself from the table and walked under her own power out of the procedure room and was discharged shortly after with no pain prescription provided other than over the counter pain relief medicines.

Case Two: Male, 42 year old, L5, two joints treated. Patient had an injected local only at the facet joint. At the end of the procedure the patient moved from the table and walked out of the procedure room on their own power and was discharged shortly after, again no pain relief prescriptions provided only over the counter medicines recommended. A picture of Dr. Deeg and patient may be found here on the Company's Facebook page: https://www.facebook.com/medovex/

Dr. Martin Deeg stated, "Both of the first two DenerveX™ System cases met with what I consider excellent initial success. Both patients experienced initial pain reduction of the Facet Joint during the actual running of the device. Additionally, both patients walked out of the procedure room on their own power and were discharged shortly following the procedure."

Deeg concluded, "I am pleased to see the very positive initial results of the procedures, the DenerveX System has great potential in the treatment of Facet Joint Pain and could become the new standard of care."

The Company previously announced it had completed first human use cases for the DenerveX System in Manchester, England with very encouraging initial procedural success. The Company anticipates performing up to as many as 30 plus procedures by the end of August and intends to update patient longer term progress, expected to be approximately 90 day post procedure.

The DenerveX System recently received CE Mark approval and clearance for commercialization in the European countries and offers a unique way to perform a Facet Joint Syndrome treatment.

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in the United States and other countries in the EU and Rest of World affecting millions each year. Current treatment options are generally temporary and there is no proven long-lasting option for FJS.

The DenerveX System is a highly differentiated technology. It denervates and removes capsular tissue from the Facet Joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and RF ablation treatment on the Facet Joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.

The DenerveX System consists of the DenerveX Kit which contains the DenerveX Device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet FDA cleared.